OCT 18, 2019 11:00 AM PDT

AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The product provides innovative standards for analytical BCR-ABL test methods in chronic myeloid leukemia (CML) disease. 

Chronic myeloid leukemia (CML) is a cancer of the blood-forming cells, called myeloid cells, found in the bone marrow. In CML, the bone marrow produces more white blood cells that usually are involved in fighting infection. 

BCR-ABL1 is a gene sequence that confirms the diagnosis of Chronic Myeloid Leukemia (CML), persistent bone marrow cancer. The detected gene is present in abnormal chromosome 22 of humans. In CML, part of chromosome 9 breaks off and bonds to a section of chromosome 22, forming the fusion chromosome. The abnormal BCR-ABL1 gene encodes an abnormal protein (tyrosine kinase) that is responsible for the development of CML.

Different testing types (cytogenetics, fluorescence in-situ hybridization, genetic molecular) are available to diagnose CML. The Acrometrix BCR-ABL external control panel is launched to quantitate BCR-ABL RNA accurately. The first of its kind, the product is useful to make a critical, timely, patient treatment decisions. The test product intends for research-use-only. The testing method can monitor assay performance at every clinical stage due to its expanded dynamic range.

"The Acrometrix BCR-ABL Panel is the first full-process molecular control for challenging validated BCR-ABL assay performance, providing researchers and laboratorians with greater confidence utilizing a highly characterized product," said Fernando Beils, vice president and general manager of Clinical Diagnostics for Thermo Fisher. "Additionally, this new molecular control panel is traceable to the new World Health Organization (WHO) standards for genetic reference panels for the quantitation of BCR-ABL. This provides assurance to laboratory staff that there is accuracy in the measurement of their assay results."

Sources: AmericanCancerSociety, ThermoFisherScientific

About the Author
You May Also Like
NOV 15, 2019
Health & Medicine
NOV 15, 2019
Novel Gene Therapy Approved by FDA to Treat Spinal Muscular Atrophy in Pediatric Patients
The most common form of spinal muscular atrophy (SMA), a rare genetic disease, is caused by mutations of chromosome 5 in the gene, SMN1. SMN1 encodes...
NOV 15, 2019
Health & Medicine
NOV 15, 2019
Emerging Arbovirus Infections in the Americas
Arboviruses are arthropod-borne pathogens with more than 130 strains known to cause human infections. The majority of these strains belong to three genera:...
NOV 15, 2019
Immunology
NOV 15, 2019
Making Opioids Safer
The opioid crisis results in 130 American deaths every day, and both prescribed and synthetic opioids are at the core of the epidemic.  Any other drug...
NOV 15, 2019
Cannabis Sciences
NOV 15, 2019
Arthritis Foundation Gives Cautious Thumbs Up for CBD Use
After a national survey in July confirmed that the vast majority of arthritis patients were either interested in using CBD for symptom relief or already us...
NOV 15, 2019
Clinical & Molecular DX
NOV 15, 2019
Patients can Self-Inject Easily Using an Integrated Pre-Filled Syringe and Autoinjector
The patients suffering from chronic disease require a regular dose of medicines, either orally or as injections. To prevent a monthly visit...
NOV 15, 2019
Immunology
NOV 15, 2019
Allergy Shots May Work for Kids with Pollen Food Allergy Syndrome
It’s not common for young children to develop pollen food allergy syndrome (PFAS), but for those that do, there’s not too much parents can do o...
Loading Comments...